Fluorometholone

證據等級: L5

預測適應症: 10 個

Fluorometholone: From Ophthalmic Inflammation to Postinfectious Vasculitis

One-Sentence Summary

Fluorometholone (FML) is a topical ophthalmic corticosteroid used for allergic and inflammatory eye conditions, not currently registered in Canada. The TxGNN model’s top prediction is Postinfectious Vasculitis (score 99.91%), though this indication has no clinical trial or literature support. Across all 10 predicted indications, the strongest clinical evidence belongs to Post-bacterial Disorder (rank 2), backed by 2 clinical trials totalling 328 patients.

Quick Overview

Item	Content
Original Indication	Not registered in Canada; known ophthalmic anti-inflammatory use
Predicted New Indication	Postinfectious Vasculitis (rank 1)
TxGNN Prediction Score	99.91%
Evidence Level	L5 (model prediction only — for rank 1)
Canada Market Status	Not marketed
Number of DINs	0
Recommended Decision	Hold (rank 1) / Proceed with Guardrails (rank 2)

Why Is This Prediction Reasonable?

Detailed mechanism of action data is not currently available in the dataset. Based on established pharmacology, fluorometholone is a fluorinated glucocorticoid formulated exclusively for ophthalmic topical use. It exerts anti-inflammatory effects primarily by suppressing the NF-κB signalling pathway and reducing pro-inflammatory cytokines (IL-1β, TNF-α), with a well-recognised advantage of lower intraocular pressure (IOP)-elevating potential compared to prednisolone acetate or dexamethasone.

The TxGNN prediction of efficacy in postinfectious vasculitis draws on corticosteroids’ general ability to suppress immune-mediated vascular inflammation. However, there is a fundamental pharmacokinetic mismatch: fluorometholone is designed as a topical ophthalmic preparation with negligible systemic bioavailability. It cannot achieve therapeutic plasma concentrations needed to treat systemic vascular conditions, making the rank 1 prediction mechanistically plausible at the class level but pharmacologically non-viable for this specific drug.

The biologically coherent cluster among all 10 predictions centres on post-infectious ocular inflammatory states — particularly post-bacterial corneal disorders (rank 2) and punctate epithelial keratoconjunctivitis (rank 6) — where fluorometholone’s known ophthalmic mechanism, route of administration, and tissue distribution directly align with the pathology.

Clinical Trial Evidence

The following trials are drawn from Post-bacterial Disorder (rank 2), the best-evidenced prediction. The top-ranked indication (postinfectious vasculitis) has no registered clinical trials.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07308938	Phase 2	Not Yet Recruiting	174	Fluorometholone 0.1% as adjunctive therapy to topical antibiotics for bacterial corneal ulcers; primary endpoint: best-corrected visual acuity (BCVA) at 3 months. Well-powered, mature design.
NCT01949454	N/A	Completed	154	Perioperative fluorometholone following trachoma-related trichiasis surgery (Chlamydia trachomatis infection); evaluates whether post-operative anti-inflammatory therapy reduces recurrent trichiasis and scarring.

Literature Evidence

The following publications relate to Punctate Epithelial Keratoconjunctivitis (rank 6), the only predicted indication with literature support.

PMID	Year	Type	Journal	Key Findings
35128186	2021	Observational / Diagnostic	Journal of Current Ophthalmology	AS-OCT imaging characterises epidemic keratoconjunctivitis (EKC) phases and demonstrates measurable impact of topical steroid on disease course
34011737	2021	Case Series / Review	Indian Journal of Ophthalmology	Characterises sequelae of microsporidial keratoconjunctivitis and outlines management including anti-inflammatory approaches

Canada Market Information

Fluorometholone is not currently marketed in Canada — no DINs are on record in the source dataset, and no approved indications are available for review.

Note: Fluorometholone ophthalmic preparations (e.g., FML® 0.1% eye drops) are marketed in multiple international jurisdictions including the United States. A direct query to Health Canada’s Drug Product Database (DPD) is recommended to confirm whether any historical or current DIN exists, as this may represent a data gap rather than a true absence from the Canadian market.

Safety Considerations

Complete safety data is not available in the current dataset. The following considerations are based on drug class pharmacology and should be verified against the product monograph:

Intraocular pressure elevation: Steroid-induced ocular hypertension is a class risk for all ophthalmic corticosteroids. Fluorometholone has a lower IOP-elevating profile than prednisolone or dexamethasone, but IOP monitoring remains necessary for courses exceeding 10 days.
Risk of masking infection: Topical corticosteroids may suppress visible signs of ocular infection. Use without adequate antimicrobial coverage in bacterial or viral settings carries risk of infection spread or worsening.
Contraindications (class-based): Generally contraindicated in active herpes simplex viral keratitis; use with caution in fungal or mycobacterial ocular infections.
Safety signal for rank 7 (infection-related HUS) and rank 8 (Chagas cardiomyopathy): Corticosteroid use may worsen STEC-mediated toxin injury in HUS, and may promote Trypanosoma cruzi reactivation in Chagas disease. These predictions carry explicit safety concerns and should not be pursued.

Conclusion and Next Steps

Decision: Hold — Rank 1 (Postinfectious Vasculitis)

Rationale: Fluorometholone’s negligible systemic bioavailability makes it pharmacologically unsuitable for treating systemic vascular inflammation. The rank 1 TxGNN prediction is mechanistically coherent at the corticosteroid class level but non-viable for this specific topical formulation. No clinical or literature evidence exists to support further investigation.

Secondary Decision: Proceed with Guardrails — Rank 2 (Post-bacterial Disorder)

Rationale: The most actionable repurposing opportunity is bacterial corneal ulcer adjunctive therapy (NCT07308938, Phase 2, n=174), directly aligned with fluorometholone’s ophthalmic route and anti-inflammatory mechanism. This is a drug-in-class effect, and the trial design is statistically powered.

To proceed with rank 2 investigation, the following is needed:

Confirm Health Canada DPD status (whether FML ophthalmic is registered under any DIN not captured in this dataset)
Retrieve full MOA data from DrugBank (data gap DG002)
Obtain TFDA package insert warnings and contraindications (data gap DG001)
Establish IOP monitoring guardrails for any protocol using fluorometholone beyond standard duration
Monitor NCT07308938 results (expected completion December 2030)
Review NCT01949454 full results for lessons on perioperative anti-inflammatory dosing in infectious disease contexts
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.